Roivant Sciences (ROIV) Gets a Buy from Leerink Partners
In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...
Leerink Partnrs Issues Positive Estimate for Opthea Earnings
Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October ...
Election to Play Key Role in Insurer Tie-Up Plan, Analysts Say
Prospects for a potential merger between health insurers Cigna Group and Humana Inc. hinge on the upcoming US presidential ...
bovnews2d
MNMD’s Latest Surge: What’s Behind the Spike?
As of the latest trading close, MNMD, a Healthcare sector stock, is trading -45.91% below its 52-week high but remains 174.27% above its 52-week low. The Average True Range (ATR) (14 days) of 0.34 ...
Leerink Partnrs Has Negative Outlook of Biohaven Q3 Earnings
Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for Biohaven in a report released ...
Mind Medicine assumed with an Outperform at Leerink
Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging ...
bovnews17h
What’s Behind the 2.24% Gain in Aquestive Therapeutics Inc (AQST) Stock? Find Out Now!
On Friday, Aquestive Therapeutics Inc (AQST) stock saw a modest uptick, ending the day at $5.03 which represents a slight increase of $0.11 or 2.24% from the prior close of $4.92. The stock opened at ...
Seeking Alpha24d
Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal
Leerink Partners downgraded Agios Pharmaceuticals (NASDAQ:AGIO) to Market Perform from Outperform on Friday, citing headwinds from Pfizer's (NYSE:PFE) recent decision to withdraw Oxbryta ...
Nasdaq27d
Leerink Partners Initiates Coverage of Voyager Therapeutics (VYGR) with Outperform Recommendation
Fintel reports that on October 16, 2024, Leerink Partners initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Outperform recommendation. As of September 25, 2024, the average one ...
Investing3d
Leerink maintains Market Perform rating on Amylyx stock on new data
Leerink Partners has maintained its Market Perform rating and $4.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). The firm acknowledged the encouraging new HELIOS open-label data for ...